Christophe Pannecouque

List of Publications by Year
in descending order

509 papers	16,778 citations	17440 63 h-index	39675 94 g-index
575 all docs	575 docs citations	575 times ranked	14335 citing authors

#	Article	IF	Citations
1	From design to biological mechanism evaluation of phenylalanine-bearing HIV-1 capsid inhibitors targeting a vital assembly interface. Chinese Chemical Letters, 2023, 34, 107611.	9.0	6
2	Linker optimization of HEPT derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors: From S=O to CHOR. Chinese Chemical Letters, 2023, 34, 107663.	9.0	2
3	Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability. European Journal of Medicinal Chemistry, 2022, 227, 113903.	5.5	11
4	Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIVâ€‘1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2022, 53, 116531.	3.0	8
5	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK. Journal of Medicinal Chemistry, 2022, 65, 2122-2138.	6.4	10
6	Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C. Journal of Medicinal Chemistry, 2022, 65, 2458-2470.	6.4	10
7	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 3729-3757.	6.4	33
8	Structure-Based Discovery of Novel NH₂-Biphenyl-Diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH₂-Naphthyl-Diarylpyrimidine to NH₂-Biphenyl-Diarylpyrimidine. Journal of Medicinal Chemistry, 2022, 65, 8478-8492.	6.4	4
9	Expansion of the Sâ€“CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry, 2022, 238, 114512.	5.5	3
10	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features. European Journal of Medicinal Chemistry, 2022, 238, 114471.	5.5	6
11	Structure-Based design of [(2-Hydroxyethoxy)methyl]-6-(phenylthio)-thymine derivatives as nonnucleoside HIV-1 reverse transcriptase Inhibitors: From HEPTs to Sulfinyl-substituted HEPTs. Bioorganic Chemistry, 2022, 126, 105880.	4.1	2
12	Discovery of novel biphenyl-substituted pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with promising oral bioavailability. European Journal of Medicinal Chemistry, 2022, 240, 114581.	5.5	5
13	Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors. European Journal of Medicinal Chemistry, 2022, 240, 114563.	5.5	4
14	Design, synthesis, and biological evaluation of piperidinylâ€substituted [1,2,4]triazolo[1,5â€a]pyrimidine derivatives as potential antiâ€HIVâ€1 agents with reduced cytotoxicity. Chemical Biology and Drug Design, 2021, 97, 67-76.	3.2	16
15	Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Chinese Chemical Letters, 2021, 32, 1020-1024.	9.0	7
16	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C. Bioorganic and Medicinal Chemistry, 2021, 30, 115927.	3.0	11
17	Design, synthesis, and evaluation of â€œdual-siteâ€•binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry, 2021, 211, 113063.	5.5	15
18	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties. European Journal of Medicinal Chemistry, 2021, 213, 113051.	5.5	15

#	Article	IF	Citations
19	Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chemical Society Reviews, 2021, 50, 4514-4540.	38.1	84
20	Boronic acid-containing diarylpyrimidine derivatives as novel HIV-1 NNRTIs: Design, synthesis and biological evaluation. Chinese Chemical Letters, 2021, 32, 4053-4057.	9.0	16
21	Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket. European Journal of Medicinal Chemistry, 2021, 214, 113204.	5.5	6
22	2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies. Journal of Medicinal Chemistry, 2021, 64, 4239-4256.	6.4	33
23	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from N-Alkylation to Methyl Hopping on the Pyrimidine Ring. Journal of Medicinal Chemistry, 2021, 64, 5067-5081.	6.4	12
24	Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity. Bioorganic Chemistry, 2021, 111, 104905.	4.1	3
25	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2021, 40, 116195.	3.0	5
26	A Novel Series of Indole Alkaloid Derivatives Inhibit Dengue and Zika Virus Infection by Interference with the Viral Replication Complex. Antimicrobial Agents and Chemotherapy, 2021, 65, e0234920.	3.2	13
27	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. Bioorganic and Medicinal Chemistry, 2021, 42, 116239.	3.0	3
28	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs. Journal of Medicinal Chemistry, 2021, 64, 10297-10311.	6.4	15
29	Discovery of Novel Dihydrothiopyrano[4,3-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles. Journal of Medicinal Chemistry, 2021, 64, 13658-13675.	6.4	14
30	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2021, 64, 13604-13621.	6.4	10
31	Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP. Bioorganic Chemistry, 2021, 116, 105353.	4.1	5
32	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors. European Journal of Medicinal Chemistry, 2021, 225, 113769.	5.5	9
33	Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors. European Journal of Medicinal Chemistry, 2021, 226, 113848.	5.5	15
34	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. European Journal of Medicinal Chemistry, 2021, 226, 113868.	5.5	10
35	Deciphering the Role of Extracellular Vesicles Derived from ZIKV-Infected hcMEC/D3 Cells on the Bloodâ€“Brain Barrier System. Viruses, 2021, 13, 2363.	3.3	8
36	Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs. Acta Pharmaceutica Sinica B, 2020, 10, 878-894.	12.0	39

#	Article	IF	Citations
37	Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles. ACS Infectious Diseases, 2020, 6, 787-801.	3.8	26
38	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2020, 185, 111874.	5.5	9
39	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. European Journal of Medicinal Chemistry, 2020, 186, 111864.	5.5	21
40	Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Acta Pharmaceutica Sinica B, 2020, 10, 344-357.	12.0	29
41	Fragment-based discovery of sulfur-containing diarylbenzopyrimidines as novel nonnucleoside reverse transcriptase inhibitors. Chinese Chemical Letters, 2020, 31, 764-768.	9.0	25
42	Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years. Acta Pharmaceutica Sinica B, 2020, 10, 961-978.	12.0	79
43	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. European Journal of Medicinal Chemistry, 2020, 206, 112811.	5.5	10
44	Synthesis, In Vitro Anti-HIV Activity, Cytotoxicity, and Computational Studies of Some New Steroids and Their Pyrazoline and Oxime Analogues. Russian Journal of Bioorganic Chemistry, 2020, 46, 822-836.	1.0	4
45	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127287.	2.2	3
46	1,2,4-Triazolo[1,5-a]pyrimidines as a Novel Class of Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. Molecules, 2020, 25, 1183.	3.8	23
47	Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives. Bioorganic and Medicinal Chemistry, 2020, 28, 115431.	3.0	10
48	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP. European Journal of Medicinal Chemistry, 2020, 193, 112237.	5.5	23
49	Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy. Molecules, 2020, 25, 1050.	3.8	11
50	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2020, 202, 112549.	5.5	13
51	Structureâ€“Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. ACS Infectious Diseases, 2020, 6, 2225-2234.	3.8	12
52	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel. Journal of Medicinal Chemistry, 2020, 63, 1298-1312.	6.4	37
53	Privileged scaffold inspired design of novel oxime-biphenyl-DAPYs in treatment of HIV-1. Bioorganic Chemistry, 2020, 99, 103825.	4.1	14
54	Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs. Molecules, 2020, 25, 1581.	3.8	8

#	Article	IF	Citations
55	Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2020, 63, 4837-4848.	6.4	50
56	Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. Journal of Medicinal Chemistry, 2020, 63, 4790-4810.	6.4	41
57	Tryptophan Trimers and Tetramers Inhibit Dengue and Zika Virus Replication by Interfering with Viral Attachment Processes. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	8
58	Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic Chemistry, 2020, 96, 103595.	4.1	11
59	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2019, 182, 111603.	5.5	22
60	Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing. European Journal of Medicinal Chemistry, 2019, 182, 111619.	5.5	16
61	Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase. Bioorganic and Medicinal Chemistry, 2019, 27, 3836-3845.	3.0	12
62	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. Communications Chemistry, 2019, 2, .	4.5	24
63	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles. Journal of Medicinal Chemistry, 2019, 62, 11430-11436.	6.4	32
64	Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126721.	2.2	12
65	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. Journal of Medicinal Chemistry, 2019, 62, 2083-2098.	6.4	66
66	Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains. European Journal of Medicinal Chemistry, 2019, 176, 11-20.	5.5	11
67	Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains. Bioorganic Chemistry, 2019, 89, 102974.	4.1	21
68	Molecular design opportunities presented by solventâ€exposed regions of target proteins. Medicinal Research Reviews, 2019, 39, 2194-2238.	10.5	28
69	Overview of Recent Strategic Advances in Medicinal Chemistry. Journal of Medicinal Chemistry, 2019, 62, 9375-9414.	6.4	108
70	Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus. Organic and Biomolecular Chemistry, 2019, 17, 3202-3217.	2.8	39
71	Design, synthesis, and biologic evaluation of novel galloyl derivatives as <scp>HIV</scp>â€1 <scp>RN</scp>ase H inhibitors. Chemical Biology and Drug Design, 2019, 93, 582-589.	3.2	14
72	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2019, 27, 447-456.	3.0	24

#	Article	IF	Citations
73	Identification of Dihydrofuro[3,4-d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. Journal of Medicinal Chemistry, 2019, 62, 1484-1501.	6.4	70
74	From cycloheptathiophene-3-carboxamide to oxazinone-based derivatives as allosteric HIV-1 ribonuclease H inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 55-74.	5.2	16
75	Discovery of potent <scp>HIV</scp>â€1 nonâ€nucleoside reverse transcriptase inhibitors by exploring the structureâ€“activity relationship of solventâ€exposed regions I. Chemical Biology and Drug Design, 2019, 93, 430-437.	3.2	13
76	Synthesis and Biological Activity of N-(arylsulfonyl) Valine Hydrazones and Assistance of NMR Spectroscopy for Definitive 3D Structure. Letters in Drug Design and Discovery, 2019, 16, 974-983.	0.7	3
77	Design and Synthesis of WM5 Analogues as HIV-1 TAR RNA Binders. Open Medicinal Chemistry Journal, 2019, 13, 16-28.	2.4	2
78	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1348-1351.	2.2	13
79	Anti-HIV activity of new higher order G-quadruplex aptamers obtained from tetra-end-linked oligonucleotides. Organic and Biomolecular Chemistry, 2018, 16, 2349-2355.	2.8	16
80	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the â€œNNRTI Adjacentâ€• Binding Site. ACS Medicinal Chemistry Letters, 2018, 9, 334-338.	2.8	32
81	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. ACS Medicinal Chemistry Letters, 2018, 9, 370-375.	2.8	28
82	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2. Bioorganic and Medicinal Chemistry, 2018, 26, 2051-2060.	3.0	10
83	Silibinin phosphodiester glyco-conjugates: Synthesis, redox behaviour and biological investigations. Bioorganic Chemistry, 2018, 77, 349-359.	4.1	17
84	Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorganic and Medicinal Chemistry, 2018, 26, 661-674.	3.0	26
85	Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored â€œhydrophobic channelâ€• Organic and Biomolecular Chemistry, 2018, 16, 1014-1028.	2.8	26
86	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1. European Journal of Medicinal Chemistry, 2018, 145, 726-734.	5.5	42
87	New findings on the d(TGGGAG) sequence: Surprising anti-HIV-1 activity. European Journal of Medicinal Chemistry, 2018, 145, 425-430.	5.5	11
88	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. European Journal of Medicinal Chemistry, 2018, 151, 339-350.	5.5	68
89	Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3472-3476.	2.2	65
90	Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3491-3495.	2.2	16

#	Article	IF	Citations
91	Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors. ELife, 2018, 7, .	6.0	57
92	Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors. Chemical Biology and Drug Design, 2018, 92, 2009-2021.	3.2	16
93	Graphene Quantum Dots Based Systems As HIV Inhibitors. Bioconjugate Chemistry, 2018, 29, 3084-3093.	3.6	111
94	5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase. European Journal of Medicinal Chemistry, 2018, 155, 714-724.	5.5	31
95	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. European Journal of Medicinal Chemistry, 2017, 130, 209-222.	5.5	30
96	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR. Bioorganic and Medicinal Chemistry, 2017, 25, 2491-2497.	3.0	26
97	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. Journal of Medicinal Chemistry, 2017, 60, 4424-4443.	6.4	79
98	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. Bioorganic and Medicinal Chemistry, 2017, 25, 4397-4406.	3.0	23
99	Synthesis and antiviral evaluation of base-modified deoxythreosyl nucleoside phosphonates. Organic and Biomolecular Chemistry, 2017, 15, 5513-5528.	2.8	4
100	Searching for novel N 1 -substituted benzimidazol-2-ones as non-nucleoside HIV-1 RT inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3861-3870.	3.0	14
101	New chalcones and thiopyrimidine analogues derived from mefenamic acid: microwave-assisted synthesis, anti-HIV activity and cytotoxicity as antileukemic agents. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2017, 72, 249-256.	0.7	8
102	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1640-1643.	2.2	14
103	Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP. ACS Medicinal Chemistry Letters, 2017, 8, 1188-1193.	2.8	30
104	Bioactive Natural Products Prioritization Using Massive Multi-informational Molecular Networks. ACS Chemical Biology, 2017, 12, 2644-2651.	3.4	112
105	1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. Bioorganic and Medicinal Chemistry, 2017, 25, 5779-5789.	3.0	16
106	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs. European Journal of Medicinal Chemistry, 2017, 140, 383-391.	5.5	12
107	Synthesis, crystal structure, anti-HIV, and antiproliferative activity of new pyrazolylthiazole derivatives. Medicinal Chemistry Research, 2017, 26, 2653-2665.	2.4	29
108	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. European Journal of Medicinal Chemistry, 2017, 126, 190-201.	5.5	17

#	Article	IF	Citations
109	Discovery of Biphenyl-Substituted Diarylpyrimidines as New Non-Nucleoside HIV-1 Reverse Transcripttase Inhibitors. Proceedings (mdpi), 2017, 1, 220.	0.2	0
110	Application of the Triazolization Reaction to Afford Dihydroartemisinin Derivatives with Anti-HIV Activity. Molecules, 2017, 22, 303.	3.8	36
111	Chelation Motifs Affecting Metal-dependent Viral Enzymes: Nâ€²-acylhydrazone Ligands as Dual Target Inhibitors of HIV-1 Integrase and Reverse Transcriptase Ribonuclease H Domain. Frontiers in Microbiology, 2017, 8, 440.	3.5	27
112	Structural Modifications of Diarylpyrimidine-quinolone Hybrids as Potent HIV-1 NNRTIs with an Improved Drug Resistance Profile. Current Pharmaceutical Design, 2017, 22, 6982-6987.	1.9	5
113	Synthesis, and prediction of molecular properties and antimicrobial activity of some acylhydrazones derived from N-(arylsulfonyl)methionine. Turkish Journal of Chemistry, 2016, 40, 510-534.	1.2	15
114	Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. Chemical Biology and Drug Design, 2016, 87, 283-289.	3.2	8
115	Design, synthesis, and biological evaluation of novel 5â€Alkylâ€6â€Adamantylmethylpyrimidinâ€4(3H)â€ones as <scp>HIV</scp>â€1 nonâ€nucleoside reverseâ€transcriptase inhibitors. Chemical Biology and Drug Design, 2016, 88, 380-385.	3.2	2
116	Studies on Cycloheptathiopheneâ€3â€carboxamide Derivatives as Allosteric HIVâ€1 Ribonucleaseâ€…H Inhibitors. ChemMedChem, 2016, 11, 1709-1720.	3.2	15
117	1,6-Bis[(benzyloxy)methyl]uracil derivativesâ€”Novel antivirals with activity against HIV-1 and influenza H1N1 virus. Bioorganic and Medicinal Chemistry, 2016, 24, 2476-2485.	3.0	8
118	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 121, 352-363.	5.5	27
119	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy. Bioorganic and Medicinal Chemistry, 2016, 24, 3006-3022.	3.0	8
120	The G-quadruplex-forming aptamer AS1411 potently inhibits HIV-1 attachment to the host cell. International Journal of Antimicrobial Agents, 2016, 47, 311-316.	2.5	50
121	Design, synthesis and anti-HIV activity of novel quinoxaline derivatives. European Journal of Medicinal Chemistry, 2016, 117, 230-240.	5.5	47
122	Synthesis, crystal structure, anti-HIV, and antiproliferative activity of new oxadiazole and thiazole analogs. Medicinal Chemistry Research, 2016, 25, 2399-2409.	2.4	34
123	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. Bioorganic and Medicinal Chemistry, 2016, 24, 4424-4433.	3.0	12
124	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. Journal of Medicinal Chemistry, 2016, 59, 7991-8007.	6.4	107
125	Amino acid derivatives. Part 6. Synthesis, in vitro antiviral activity and molecular docking study of new N-Î±-amino acid derivatives conjugated spacer phthalimide backbone. Medicinal Chemistry Research, 2016, 25, 2578-2588.	2.4	7
126	Design, Synthesis, and Molecular Docking Studies of a Conjugated Thiadiazoleâ€“Thiourea Scaffold as Antituberculosis Agents. Biological and Pharmaceutical Bulletin, 2016, 39, 502-515.	1.4	32

#	Article	IF	Citations
127	Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5â€b]pyridinâ€2â€ylthioacetanilides as Potent HIV NNRTIs Via a Structureâ€based Bioisosterism Approach. Chemical Biology and Drug Design, 2016, 88, 241-253.	3.2	12
128	Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. Journal of Medicinal Chemistry, 2016, 59, 9513-9531.	6.4	26
129	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells. European Journal of Medicinal Chemistry, 2016, 121, 58-70.	5.5	73
130	Modification of the length and structure of the linker of N6-benzyladenosine modulates its selective antiviral activity against enterovirus 71. European Journal of Medicinal Chemistry, 2016, 111, 84-94.	5.5	29
131	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 115, 53-62.	5.5	21
132	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 109, 294-304.	5.5	28
133	A new vinyl selenone-based domino approach to spirocyclopropyl oxindoles endowed with anti-HIV RT activity. Organic and Biomolecular Chemistry, 2016, 14, 2015-2024.	2.8	57
134	Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. Journal of Medicinal Chemistry, 2016, 59, 2849-2878.	6.4	260
135	The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition. PLoS ONE, 2016, 11, e0147773.	2.5	12
136	Synthesis and in Vitro Antiviral Activities of [(Dihydrofuranâ€2â€yl)oxy]methylâ€phosphonate Nucleosides with 2â€Substituted Adenine as Base. Chemistry and Biodiversity, 2015, 12, 813-822.	2.1	5
137	Synthesis and biological evaluation of some new 1,3,4-thiadiazole and 1,2,4-triazole derivatives from L-methionine as antituberculosis and antiviral agents. Marmara Pharmaceutical Journal, 2015, 2, 88-88.	0.5	16
138	Regioselective Suzukiâ€“Miyaura reactions of 4,7-dichloro-N-methylisatin. Synthesis, anti-HIV activity and modeling study. RSC Advances, 2015, 5, 107360-107369.	3.6	5
139	Scaffold hopping: Exploration of acetanilide-containing uracil analogues as potential NNRTIs. Bioorganic and Medicinal Chemistry, 2015, 23, 1069-1081.	3.0	14
140	Synthesis and biological evaluation of DAPYâ€“DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic and Medicinal Chemistry, 2015, 23, 624-631.	3.0	13
141	Design, synthesis of new Î²-carboline derivatives and their selective anti-HIV-2 activity. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1232-1235.	2.2	49
142	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. European Journal of Medicinal Chemistry, 2015, 93, 330-337.	5.5	41
143	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. European Journal of Medicinal Chemistry, 2015, 92, 754-765.	5.5	76
144	Synthesis and Biological Evaluation of a Series of 2â€((1â€substitutedâ€1Hâ€1,2,3â€triazolâ€4â€yl)methylthio)â€6â€(naphthalenâ€1â€ylmethyl)pyrimidinâ€4(3H)â€one Potential <scp>HIV</scp>â€1 Inhibitors. Chemical Biology and Drug Design, 2015, 86, 614-618.	1.7	4

#	Article	IF	Citations
145	Synthesis and Preliminary Antiviral Activities of Piperidineâ€substituted Purines against <scp>HIV</scp> and Influenza A/H1N1 Infections. Chemical Biology and Drug Design, 2015, 86, 568-577.	3.2	17
146	Design, Synthesis, and Biological Evaluation of Novel 4â€Aminopiperidinylâ€linked 3,5â€Disubstitutedâ€1,2,6â€thiadiazineâ€1,1â€dione Derivatives as <scp>HIV</scp>â€1 <scp>NNRTI</scp>s. Chemical Biology and Drug Design, 2015, 86, 107-113.	3.2	6
147	Hybrid chemistry. Part 4: Discovery of etravirineâ€"VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 4248-4255.	3.0	25
148	Anti-HIV diarylpyrimidineâ€"quinolone hybrids and their mode of action. Bioorganic and Medicinal Chemistry, 2015, 23, 3860-3868.	3.0	25
149	Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication. Journal of Natural Products, 2015, 78, 1277-1283.	3.0	62
150	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2015, 97, 1-9.	5.5	23
151	Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata. Journal of Natural Products, 2015, 78, 1119-1128.	3.0	39
152	Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma. EBioMedicine, 2015, 2, 1102-1113.	6.1	24
153	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue. European Journal of Medicinal Chemistry, 2015, 102, 215-222.	5.5	23
154	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities. Bioorganic and Medicinal Chemistry, 2015, 23, 6587-6593.	3.0	23
155	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity. Journal of Medicinal Chemistry, 2015, 58, 9601-9614.	6.4	175
156	Structural modification of diarylpyrimidine derivatives as HIV-1 reverse transcriptase inhibitors. Medicinal Chemistry Research, 2015, 24, 220-225.	2.4	11
157	Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Antiâ€HIVâ€1 Agents. Chemical Biology and Drug Design, 2015, 86, 333-343.	3.2	0
158	Design, Synthesis, and Antiâ€<scp>HIV</scp> Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the <scp>NNRTI</scp> Binding Pocket. Chemical Biology and Drug Design, 2015, 86, 122-128.	3.2	18
159	Synthesis and anti-HIV activity of carboxylated and drug-conjugated multi-walled carbon nanotubes. Carbon, 2015, 82, 548-561.	10.3	55
160	G-Quadruplexes in the Human Immunodeficiency Virus-1 and Herpes Simplex Virus-1: New Targets for Antiviral Activity by Small Molecules. IFMBE Proceedings, 2015, , 207-210.	0.3	4
161	Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma. Blood, 2015, 126, 2751-2751.	1.4	1
162	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. European Journal of Medicinal Chemistry, 2014, 76, 531-538.	5.5	19

#	Article	IF	Citations
163	Discovery of HIVâ€1 Integrase Inhibitors: Pharmacophore Mapping, Virtual Screening, Molecular Docking, Synthesis, and Biological Evaluation. Chemical Biology and Drug Design, 2014, 83, 154-166.	3.2	13
164	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: Design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. Bioorganic and Medicinal Chemistry, 2014, 22, 2052-2059.	3.0	71
165	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays. Bioorganic and Medicinal Chemistry, 2014, 22, 1863-1872.	3.0	40
166	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 3220-3226.	3.0	16
167	Synthesis and Antiâ€<scp>HIV</scp> Activity of 4â€(Naphthalenâ€1â€yl)â€1,2,5â€thiadiazolâ€3â€hydroxyl Derivatives. Chemical Biology and Drug Design, 2014, 84, 420-430.	3.2	19
168	Design and synthesis of N1-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 1459-1467.	3.0	44
169	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2014, 22, 633-642.	3.0	21
170	A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity. Antiviral Research, 2014, 112, 91-102.	4.1	24
171	Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. MedChemComm, 2014, 5, 468.	3.4	6
172	Design and synthesis of a new series of cyclopropylamino-linking diarylpyrimidines as HIV non-nucleoside reverse transcriptase inhibitors. European Journal of Pharmaceutical Sciences, 2014, 62, 334-341.	4.0	8
173	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands. Bioorganic and Medicinal Chemistry, 2014, 22, 4658-4666.	3.0	19
174	Antiretroviral activity of metal-chelating HIV-1 integrase inhibitors. European Journal of Medicinal Chemistry, 2014, 83, 594-600.	5.5	21
175	Sydnone Sulfonamide Derivatives as Antibacterial, Antifungal, Antiproliferative and Anti-HIV Agents. Pharmaceutical Chemistry Journal, 2014, 48, 260-268.	0.8	14
176	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: Discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. European Journal of Medicinal Chemistry, 2014, 85, 293-303.	5.5	51
177	Anti-HIV-1 activity of the G-quadruplex ligand BRACO-19. Journal of Antimicrobial Chemotherapy, 2014, 69, 3248-3258.	3.0	115
178	Different Heterocycles Functionalized sâ€Triazine Analogues: Design, Synthesis and In Vitro Antimicrobial, Antituberculosis, and Antiâ€HIV Assessment. Journal of Heterocyclic Chemistry, 2014, 51, 1641-1658.	2.6	16
179	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 5290-5297.	3.0	11
180	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. European Journal of Medicinal Chemistry, 2014, 87, 52-62.	5.5	36

#	Article	IF	Citations
181	Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. European Journal of Medicinal Chemistry, 2014, 80, 112-121.	5.5	29
182	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 2535-2541.	3.0	12
183	Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 817-820.	2.2	5
184	Jatrophane Diterpenes as Inhibitors of Chikungunya Virus Replication: Structureâ€“Activity Relationship and Discovery of a Potent Lead. Journal of Natural Products, 2014, 77, 1505-1512.	3.0	67
185	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2014, 82, 600-611.	5.5	28
186	Design, synthesis, antimicrobial activity and anti-HIV activity evaluation of novel hybrid quinazolineâ€“triazine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 100-108.	5.2	51
187	Synthesis of novel biologically active methylene derivatives of sydnones. Medicinal Chemistry Research, 2013, 22, 5752-5763.	2.4	11
188	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6593-6597.	2.2	23
189	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: Synthesis, biological investigation and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2013, 21, 6477-6483.	3.0	8
190	Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2013, 21, 7091-7100.	3.0	10
191	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2013, 21, 7398-7405.	3.0	7
192	Synthesis and Anti-HIV-1 Activity of 1-[ï‰-(Phenoxy)Alkyl and -Alkenyl]Uracil Derivatives. Pharmaceutical Chemistry Journal, 2013, 47, 459-463.	0.8	3
193	Computerâ€Aided Design, Synthesis and Validation of 2â€Phenylquinazolinone Fragments as CDK9 Inhibitors with Antiâ€HIVâ€1 Tatâ€Mediated Transcription Activity. ChemMedChem, 2013, 8, 1941-1953.	3.2	32
194	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic and Medicinal Chemistry, 2013, 21, 1150-1158.	3.0	28
195	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2013, 21, 2128-2134.	3.0	43
196	Anti-HIV, antimycobacterial and antimicrobial studies of newly synthesized 1,2,4-triazole clubbed benzothiazoles. Medicinal Chemistry Research, 2013, 22, 1320-1329.	2.4	20
197	Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. MedChemComm, 2013, 4, 810.	3.4	8
198	Some Hydrazones of 2â€Aroylaminoâ€3â€methylbutanohydrazide: Synthesis, Molecular Modeling Studies, and Identification as Stereoselective Inhibitors of HIVâ€1. Archiv Der Pharmazie, 2013, 346, 140-153.	4.1	5

#	Article	IF	Citations
199	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2013, 65, 134-143.	5.5	19
200	Discovery of Piperidine-Linked Pyridine Analogues as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. ChemMedChem, 2013, 8, 1117-1126.	3.2	15
201	Design, Synthesis, and Evaluation of WC5 Analogues as Inhibitors of Human Cytomegalovirus Immediateâ€Earlyâ€...2 Protein, a Promising Target for Antiâ€HCMV Treatment. ChemMedChem, 2013, 8, 1403-1414.	3.2	18
202	Design, Synthesis, and Biological Evaluation of Novel 3,5â€Disubstitutedâ€1,2,6â€Thiadiazineâ€1,1â€Dione Derivatives as <scp>HIV</scp>â€1 <scp>NNRTI</scp>s. Chemical Biology and Drug Design, 2013, 82, 384-393.	3.2	6
203	Exploration of the in vitro Antiviral Activity of a Series of New Pyrimidine Analogues on the Replication of HIV and HCV. Antiviral Chemistry and Chemotherapy, 2013, 23, 103-112.	0.6	8
204	Synthesis and Biological Evaluation of Methylenecyclopropane Analogues of Nucleosides. Synthesis, 2013, 45, 2612-2618.	2.3	13
205	Synthesis and anti-HIV Activity of New Fused Chromene Derivatives Derived from 2-Amino-4-(1-naphthyl)-5-oxo-4H,5H-pyrano[3,2- c]chromene-3-carbonitrile. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2013, 68, 229-238.	0.7	22
206	Synthesis, Antimycobacterial, Antiviral, Antimicrobial Activity and QSAR Studies of N2-acyl isonicotinic Acid Hydrazide Derivatives. Medicinal Chemistry, 2013, 9, 53-76.	1.5	37
207	Artemisinin Analogues as Potent Inhibitors of In Vitro Hepatitis C Virus Replication. PLoS ONE, 2013, 8, e81783.	2.5	51
208	Diterpenoids from Euphorbiaceae with Potent Anti-CHIKV and Anti-HIV Activities: Are these Antiviral Properties Correlated?. Planta Medica, 2013, 79, .	1.3	2
209	Synthesis and Anti-HIV Evaluation of Novel 1,2,4-triazole Derivatives as Potential Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Letters in Drug Design and Discovery, 2013, 10, 27-34.	0.7	14
210	Design, Synthesis and Biological Evaluation of Substituted Guanidine Indole Derivatives as Potential Inhibitors of HIV-1 Tat-TAR Interaction. Medicinal Chemistry, 2013, 10, 738-746.	1.5	6
211	Substituted Naphthalen-1-yl-Acetic Acid Hydrazides: Synthesis, Antimicrobial Evaluation and QSAR Analysis. Medicinal Chemistry, 2013, 9, 249-274.	1.5	3
212	Arylazolylthioacetanilide. Part 11: Design, Synthesis and Biological Evaluation of 1,2,4-triazole Thioacetanilide Derivatives as Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Medicinal Chemistry, 2013, 9, 968-973.	1.5	9
213	Nitroimidazoles Part 8. Synthesis and Anti-HIV Activity of New 4-Nitroimidazole Derivatives Using the Suzuki Cross-Coupling Reaction. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2012, 67, 925-934.	0.7	9
214	Nitroimidazoles Part 7. Synthesis and Anti-HIV Activity of New 4-Nitroimidazole Derivatives. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2012, 67, 835-842.	0.7	10
215	Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2012, 58, 485-492.	5.5	5
216	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach. Bioorganic and Medicinal Chemistry, 2012, 20, 6795-6802.	3.0	15

#	Article	IF	Citations
217	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7155-7162.	2.2	50
218	Zinc(ii) complexes of constrained antiviral macrocycles. Dalton Transactions, 2012, 41, 6408.	3.3	53
219	Synthesis, and in vitro Enzymatic and Antiviral Evaluation of d4T Polyphosphate Derivatives as Chain Terminators. Chemistry and Biodiversity, 2012, 9, 2186-2194.	2.1	8
220	CXCR4 chemokine receptor antagonists: nickel(ii) complexes of configurationally restricted macrocycles. Dalton Transactions, 2012, 41, 11369.	3.3	35
221	Synthesis and in vitro enzymatic and antiviral evaluation of phosphoramidate d4T derivatives as chain terminators. Organic and Biomolecular Chemistry, 2012, 10, 146-153.	2.8	5
222	Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates. International Journal of Biological Macromolecules, 2012, 50, 974-980.	7.5	18
223	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 3856-3864.	3.0	63
224	Synthesis and Evaluation of Novel 4â€Substituted Styryl Quinazolines as Potential Antimicrobial Agents. Archiv Der Pharmazie, 2012, 345, 964-972.	4.1	13
225	A phenyl-thiadiazolylidene-amine derivative ejects zinc from retroviral nucleocapsid zinc fingers and inactivates HIV virions. Retrovirology, 2012, 9, 95.	2.0	24
226	Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines. Virology Journal, 2012, 9, 171.	3.4	21
227	Antimicrobial, anti-TB, anticancer and anti-HIV evaluation of news-triazine-based heterocycles. Future Medicinal Chemistry, 2012, 4, 1053-1065.	2.3	43
228	Arylazolyl(azinyl)thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 5527-5536.	3.0	17
229	POMA analyses as new efficient bioinformaticsâ€™ platform to predict and optimise bioactivity of synthesized 3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide/carbothioamide analogues. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7029-7035.	2.2	25
230	Synthesis and Anti-HIV Evaluation of Novel 1,2,4-triazole Derivatives as Potential Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Letters in Drug Design and Discovery, 2012, 10, 27-34.	0.7	3
231	Synthesis and anti-HIV evaluation of new 2-Thioxoimidazolidin-4-ones and their Arylidine (styryl) derivatives. Pharmaceutical Chemistry Journal, 2012, 46, 165-170.	0.8	9
232	Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies. Medicinal Chemistry Research, 2012, 21, 1451-1470.	2.4	58
233	An Efficient Synthesis of a Hydroxyethylamine (HEA) Isostere and Its Î±â€Aminophosphonate and Phosphoramidate Derivatives as Potential Antiâ€HIV Agents. ChemMedChem, 2012, 7, 1601-1611.	3.2	39
234	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of isonicotinic acid-1-(substituted phenyl)-ethylidene/cycloheptylidene hydrazides. Medicinal Chemistry Research, 2012, 21, 1935-1952.	2.4	40

#	Article	IF	Citations
235	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of nicotinic acid benzylidene hydrazide derivatives. Medicinal Chemistry Research, 2012, 21, 1557-1576.	2.4	54
236	Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. Archives of Pharmacal Research, 2012, 35, 975-986.	6.3	13
237	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2012, 51, 60-66.	5.5	42
238	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2012, 53, 229-234.	5.5	28
239	Synthesis, antiviral and cytotoxicity studies of novel N-substituted indophenazine derivatives. Indian Journal of Pharmaceutical Sciences, 2012, 74, 275.	1.0	7
240	Indolylarylsulfones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: New Cyclic Substituents at Indole-2-carboxamide. Journal of Medicinal Chemistry, 2011, 54, 1587-1598.	6.4	137
241	A Microwave-Assisted Diastereoselective Multicomponent Reaction To Access Dibenzo[c,e]azepinones: Synthesis and Biological Evaluation. Journal of Organic Chemistry, 2011, 76, 2828-2839.	3.2	77
242	Nicotinic Acid Benzylidene/Phenyl-Ethylidene Hydrazides: Synthesis, Antimicrobial Evaluation and QSAR Studies. Letters in Drug Design and Discovery, 2011, 8, 733-749.	0.7	16
243	Synthesis and an Antiviral Activity Evaluation of Nucleoside 5â€²-O-(N-acyl) Phosphoramidates. Antiviral Chemistry and Chemotherapy, 2011, 21, 143-150.	0.6	1
244	New Substituted Thiazol-2-ylidene-benzamides and Their Reaction with 1-Aza-2-azoniaallene Salts. Synthesis and anti-HIV Activity. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2011, 66, 512-520.	0.7	1
245	A time-ofâ€“drug addition approach to target identification of antiviral compounds. Nature Protocols, 2011, 6, 925-933.	12.0	108
246	Arylazolylthioacetanilide. Part 8â€ : Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides As Potent HIV-1 inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 5039-5045.	5.5	32
247	Substituted 2-aminothiazoles are exceptional inhibitors of neuronal degeneration in tau-driven models of Alzheimerâ€™s disease. European Journal of Pharmaceutical Sciences, 2011, 43, 386-392.	4.0	26
248	Synthesis and structureâ€“activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2011, 19, 5117-5124.	3.0	26
249	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents. Bioorganic and Medicinal Chemistry, 2011, 19, 5794-5802.	3.0	37
250	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2011, 19, 7093-7099.	3.0	23
251	Synthesis and antiâ€HIV activity of new 2â€thiolumazine and 2â€thiouracil metal complexes. Heteroatom Chemistry, 2011, 22, 44-50.	0.7	17
252	Synthesis and Biological Evaluation of 6â€Substituted 5â€Alkylâ€2â€(phenylaminocarbonylmethylthio)pyrimidinâ€4(3H)â€ones as Potent HIVâ€1 NNRTIs. ChemMedChem, 2011, 6, 826-833.	3.2	13

#	Article	IF	Citations
253	Structural Investigation of the Naphthyridone Scaffold: Identification of a 1,6â€Naphthyridone Derivative with Potent and Selective Antiâ€HIV Activity. ChemMedChem, 2011, 6, 1249-1257.	3.2	30
254	Synthesis and Antiâ€HIV Activity of Arylâ€2â€[(4â€cyanophenyl)amino]â€4â€pyrimidinone hydrazones as Potent Nonâ€nucleoside Reverse Transcriptase Inhibitors. ChemMedChem, 2011, 6, 2225-2232.	3.2	31
255	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 4366-4376.	3.0	30
256	Synthesis and anti-HIV Activity of New Benzimidazole, Benzothiazole and Carbohyrazide Derivatives of the anti-Inflammatory Drug Indomethacin. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2011, 66, 953-960.	0.7	8
257	Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer. RNA Biology, 2011, 8, 316-324.	3.1	10
258	Stereocontrolled Synthesis and Biological Evaluation of Novel Carbocyclic Nucleosides Analogues of Neplanocin F and Abacavir. Synlett, 2011, 2011, 111-115.	1.8	1
259	Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl-1,1,3-trioxo-2H,4H-pyrazolo[4,5-e][1,2,4]thiadiazine derivatives. Drug Discoveries and Therapeutics, 2011, , .	1.5	0
260	New Substituted Thiazol-2-ylidene-benzamides and Their Reaction with 1-Aza-2-azoniaallene Salts. Synthesis and anti-HIV Activity. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2011, 66, 0512.	0.7	9
261	Synthesis and anti-HIV Activity of New Benzimidazole, Benzothiazole and Carbohyrazide Derivatives of the anti-Inflammatory Drug Indomethacin. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2011, 66, 0953.	0.7	2
262	Z. Naturforsch. 2011, 66b, 512 - 520. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2011, 66, 0979.	0.7	2
263	Amino acid derivatives. Part 6. New analogues of the angiotensin-converting enzyme 'Captopril'. Synthesis and anti-HIV activity. Arkivoc, 2011, 2010, 242-253.	0.5	2
264	Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl-1,1,3-trioxo-2H,4H-pyrazolo[4,5-e][1,2,4]thiadiazine derivatives. Drug Discoveries and Therapeutics, 2011, 5, 279-85.	1.5	3
265	Synthesis and anti-HIV activity evaluation of novel Nâ€²-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. Medicinal Chemistry Research, 2010, 19, 652-663.	2.4	23
266	Design, synthesis and preliminary antiviral screening of new N-phenylpyrazole and dihydroisoxazole derivatives. Medicinal Chemistry Research, 2010, 19, 1025-1035.	2.4	13
267	Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle. Antiviral Research, 2010, 85, 418-421.	4.1	20
268	Lead Optimization of Diarylpyrimidines as Nonâ€nucleoside Inhibitors of HIVâ€1 Reverse Transcriptase. ChemMedChem, 2010, 5, 837-840.	3.2	28
269	Studies of Antiâ€HIV Transcription Inhibitor Quinolones: Identification of Potent N1â€Vinyl Derivatives. ChemMedChem, 2010, 5, 1880-1892.	3.2	26
270	Synthesis, In Vitro and In Vivo Release Kinetics, and Antiâ€HIV Activity of A Sustainedâ€Release Prodrug (mPEGâ€AZT) of 3â€²â€Azidoâ€3â€²â€deoxythymidine (AZT, Zidovudine). ChemMedChem, 2010, 5, 1893-1898.	3.2	27

#	Article	IF	Citations
271	Inside Cover: Studies of Anti-HIV Transcription Inhibitor Quinolones: Identification of Potent N1-Vinyl Derivatives (ChemMedChem 11/2010). ChemMedChem, 2010, 5, 1798-1798.	3.2	0
272	1,2,3â€¬Thiadiazole Thioacetanilides. Part 2. Chemistry and Biodiversity, 2010, 7, 1717-1727.	2.1	23
273	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 1702-1710.	3.0	36
274	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV. Bioorganic and Medicinal Chemistry, 2010, 18, 2370-2374.	3.0	28
275	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 4601-4605.	3.0	33
276	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy. Bioorganic and Medicinal Chemistry, 2010, 18, 5039-5047.	3.0	31
277	Anti-HIV and antiplasmodial activity of original flavonoid derivatives. Bioorganic and Medicinal Chemistry, 2010, 18, 6012-6023.	3.0	39
278	Straightforward synthesis of triazoloacyclonucleotide phosphonates as potential HCV inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7365-7368.	2.2	47
279	Synthesis, structureâ€“activity relationship and antiviral activity of 3â€²-N,N-dimethylamino-2â€²,3â€²-dideoxythymidine and its prodrugsâ˜†. European Journal of Medicinal Chemistry, 2010, 45, 3787-3793.	3.5	7
280	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: Synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation. European Journal of Medicinal Chemistry, 2010, 45, 5985-5997.	5.5	18
281	Screening of Tanzanian Medicinal Plants againstPlasmodium falciparumand Human Immunodeficiency Virus. Planta Medica, 2010, 76, 195-201.	1.3	58
282	Cytotoxicity of Natural Compounds Isolated from the Seeds ofGarcinia afzelii. Planta Medica, 2010, 76, 708-712.	1.3	18
283	Inhibition of HIV-1 Replication by a Bis-Thiadiazolbenzene-1,2-Diamine That Chelates Zinc Ions from Retroviral Nucleocapsid Zinc Fingers. Antimicrobial Agents and Chemotherapy, 2010, 54, 1461-1468.	3.2	34
284	A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication. Journal of Medicinal Chemistry, 2010, 53, 641-648.	6.4	122
285	Oxovanadium(IV) Cyclam and Bicyclam Complexes: Potential CXCR4 Receptor Antagonists. Inorganic Chemistry, 2010, 49, 1122-1132.	4.0	39
286	Phytochemical and biological investigations of Elaeodendron schlechteranum. Journal of Ethnopharmacology, 2010, 129, 319-326.	4.1	33
287	Synthesis and evaluation of antiviral, antitubercular and anticancer activities of some novel thioureas derived from 4-aminobenzohydrazide hydrazones. Marmara Pharmaceutical Journal, 2010, 1, 13-20.	0.5	20
288	Amino acid derivatives. Part 5. Synthesis and anti-HIV activity of new sebacoyl precursor derived thioureido-amino acid and phthalimide derivatives. Arkivoc, 2010, 2010, 185-195.	0.5	6

#	Article	IF	Citations
289	Synthesis, antiviral and cytotoxic activities of 2-(2-Phenyl carboxylic acid)-3-Phenylquinazolin -4(3H)-one derivatives. Indian Journal of Pharmaceutical Sciences, 2010, 72, 806.	1.0	5
290	Synthesis and Antiviral Evaluation of (-)-3â€²-Methylcarbovir, (-)-3â€²-Methylabacavir, and Modified Purine Analogues. Synthesis, 2009, 2009, 290-296.	2.3	0
291	Design Strategies of Novel NNRTIs to Overcome Drug Resistance. Current Medicinal Chemistry, 2009, 16, 3903-3917.	2.4	92
292	The Phthalocyanine Prototype Derivative Alcian Blue Is the First Synthetic Agent with Selective Anti-Human Immunodeficiency Virus Activity Due to Its gp120 Glycan-Binding Potential. Antimicrobial Agents and Chemotherapy, 2009, 53, 4852-4859.	3.2	11
293	Anti-influenza virus activity and structureâ€“activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains. Antiviral Research, 2009, 82, 89-94.	4.1	49
294	Structural Modifications of DAPY Analogues with Potent Antiâ€HIVâ€1 Activity. ChemMedChem, 2009, 4, 219-224.	3.2	43
295	Design, Synthesis, and SAR of Naphthylâ€Substituted Diarylpyrimidines as Nonâ€Nucleoside Inhibitors of HIVâ€1 Reverse Transcriptase. ChemMedChem, 2009, 4, 1537-1545.	3.2	38
296	Synthesis and Studies of New 2â€(Coumarinâ€4â€yloxy)â€4,6â€(substituted)â€sâ€Triazine Derivatives as Potential Antiâ€HIV Agents. Archiv Der Pharmazie, 2009, 342, 281-290.	4.1	54
297	Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Part 13. Chemistry and Biodiversity, 2009, 6, 561-568.	2.1	13
298	Design, synthesis, and structureâ€“activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents. Bioorganic and Medicinal Chemistry, 2009, 17, 5962-5967.	3.0	42
299	Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: Synthesis and preliminary SAR studies. Bioorganic and Medicinal Chemistry, 2009, 17, 5920-5927.	3.0	81
300	1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation. Bioorganic and Medicinal Chemistry, 2009, 17, 6374-6379.	3.0	58
301	Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 1016-1023.	5.5	21
302	Synthesis, antiviral and anticancer activity of some novel thioureas derivedfrom N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide. European Journal of Medicinal Chemistry, 2009, 44, 3591-3595.	5.5	47
303	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 4648-4653.	5.5	45
304	Sodium and potassium benzeneazophosphonate complexes with crown ethers: Solid-state microwave synthesis, characterization and biological activity. Polyhedron, 2009, 28, 3449-3458.	2.2	5
305	Structureâ€“activity relationships for dipeptide prodrugs of acyclovir: Implications for prodrug design. European Journal of Medicinal Chemistry, 2009, 44, 2339-2346.	5.5	24
306	Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 1210-1214.	5.5	31

#	Article	IF	Citations
307	Synthesis and antiviral activity of new pyrazole and thiazole derivatives. European Journal of Medicinal Chemistry, 2009, 44, 3746-3753.	5.5	284
308	Studies on anti-HIV quinolones: New insights on the C-6 position. Bioorganic and Medicinal Chemistry, 2009, 17, 667-674.	3.0	32
309	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 5775-5781.	3.0	64
310	Synthesis and biological evaluation of novel 2-(substituted) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td (phenylaminocarbonylmethylth Bioorganic and Medicinal Chemistry, 2009, 17, 7749-7754.	3.0	24
311	Synthesis and biological evaluation of new heterocyclic quinolinones as anti-parasite and anti-HIV drug candidates. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5962-5964.	2.2	41
312	Dimer Disruption and Monomer Sequestration by Alkyl Tripeptides Are Successful Strategies for Inhibiting Wild-Type and Multidrug-Resistant Mutated HIV-1 Proteases. Biochemistry, 2009, 48, 379-387.	2.5	27
313	Crystallographic Study of a Novel Subnanomolar Inhibitor Provides Insight on the Binding Interactions of Alkenyldiarylmethanes with Human Immunodeficiency Virus-1 Reverse Transcriptase. Journal of Medicinal Chemistry, 2009, 52, 6467-6473.	6.4	11
314	Binding Optimization through Coordination Chemistry: CXCR4 Chemokine Receptor Antagonists from Ultrarigid Metal Complexes. Journal of the American Chemical Society, 2009, 131, 3416-3417.	13.7	82
315	Non-nucleoside reverse transcriptase inhibitors (Part 18): synthesis and anti-HIV activity of 4-allylamino or 4-azido substituted diaryltriazines. Yaoxue Xuebao, 2009, 44, 145-9.	0.2	1
316	New synthesis and anti-HIV and antiviral properties of 3-arylsulfonyl derivatives of 4-ydroxycoumarin and 4-hydroxyquinolone. Pharmaceutical Chemistry Journal, 2008, 42, 265-270.	0.8	47
317	Dipeptide Derivatives of AZT: Synthesis, Chemical Stability, Activation in Human Plasma, hPEPT1 Affinity, and Antiviral Activity. ChemMedChem, 2008, 3, 970-978.	3.2	18
318	Synthesis and Antiâ€HIV Activity Evaluation of Novel 2,4â€Disubstituted 7â€Methylâ€1,1,3â€trioxoâ€2,4â€dihydroâ€pyrazoloâ€[4,5â€e][1,2]thiadiazines. Archiv Der Pharmazie, 2008, 341, 216-222.	1.8	8
319	Nonâ€Nucleoside HIVâ€1 Reverseâ€Transcriptase Inhibitors. Part 10. Chemistry and Biodiversity, 2008, 5, 168-176.	2.1	11
320	Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: Structural modulations of diaryltriazines with potent anti-HIV activity. European Journal of Medicinal Chemistry, 2008, 43, 1230-1236.	5.5	102
321	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. European Journal of Medicinal Chemistry, 2008, 43, 2800-2806.	5.5	97
322	Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs). Bioorganic and Medicinal Chemistry, 2008, 16, 157-163.	3.0	10
323	Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 3887-3894.	3.0	18
324	Synthesis and anti-HIV1 biological activity of novel 5â€³-ATSAO compounds. Bioorganic and Medicinal Chemistry, 2008, 16, 4733-4741.	3.0	14

#	Article	IF	Citations
325	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 7429-7435.	3.0	43
326	Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structureâ€“activity relationship and mechanism of action. Bioorganic and Medicinal Chemistry, 2008, 16, 9487-9497.	3.0	59
327	Inhibition of tubulin polymerization by select alkenyldiarylmethanes. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 469-473.	2.2	7
328	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1530-1533.	2.2	5
329	Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2277-2281.	2.2	9
330	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5368-5371.	2.2	65
331	2â€(2,6â€Dihaloâ€phenyl)â€3â€heteroarylâ€2â€ylmethylâ€1, 3â€thiazolidinâ€4â€ones: Antiâ€HIV agents. Chemical Biology and Drug Design, 2008, 72, 147-154.	3.2	21
332	Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nature Protocols, 2008, 3, 427-434.	12.0	324
333	Structureâ^'Activity Relationship Study on Anti-HIV 6-Desfluoroquinolones. Journal of Medicinal Chemistry, 2008, 51, 5454-5458.	6.4	56
334	Microwave-Assisted Synthesis and Anti-HIV Activity of New AcyclicC-Nucleosides of 3-(D-Ribo-Tetritol-1-yl)-5-Mercapto-1,2,4-Triazoles. Part 1. Nucleosides, Nucleotides and Nucleic Acids, 2008, 27, 469-483.	1.1	5
335	New AZT Analogues Having 5â€²-Alkylsulfonyl Groups: Synthesis and Anti-HIV Activity. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 223-230.	1.1	4
336	Nitroimidazoles. V. Synthesis and anti-HIV evaluation of new 5-substituted piperazinyl-4-nitroimidazole derivatives. Acta Pharmaceutica, 2007, 57, 379-393.	2.0	24
337	Novel In Vivo Model for the Study of Human Immunodeficiency Virus Type 1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives. Antimicrobial Agents and Chemotherapy, 2007, 51, 1407-1413.	3.2	19
338	Nitroimidazoles Part 6. Synthesis, Structure andin Vitroanti-HIV Activity of New 5-substituted Piperazinyl-4-nitroimidazole Derivatives. Antiviral Chemistry and Chemotherapy, 2007, 18, 191-200.	0.6	10
339	Isothiazole Derivatives as Antiviral Agents. Antiviral Chemistry and Chemotherapy, 2007, 18, 277-283.	0.6	7
340	Synthesis of Novel Derivatives of 4-Amino-3-(2-Furyl)-5-Mercapto-1,2,4-Triazole as Potential HIV-1 NNRTIs. Molecules, 2007, 12, 2003-2016.	3.8	31
341	Probing key coordination interactions: configurationally restricted metal activated CXCR4 antagonists. Dalton Transactions, 2007, , 5008.	3.3	35
342	Synthesis and Biological Evaluation of Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors That Possess Increased Hydrolytic Stability. Journal of Medicinal Chemistry, 2007, 50, 4854-4867.	6.4	31

#	Article	IF	Citations
343	Synthesis and Anti-HIV Activity of New Metabolically Stable Alkenyldiarylmethane Non-Nucleoside Reverse Transcriptase Inhibitors Incorporating N-Methoxy Imidoyl Halide and 1,2,4-Oxadiazole Systems. Journal of Medicinal Chemistry, 2007, 50, 3314-3321.	6.4	49
344	Antiviral Activity of 3-(3,5-Dimethylbenzyl)Uracil Derivatives Against Hiv-1 and HCMV. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 1553-1558.	1.1	9
345	Synthesis of novel PETT analogues: 3,4-dimethoxy phenyl ethyl 1,3,5-triazinyl thiourea derivatives and their antibacterial and anti-HIV studies. Journal of the Brazilian Chemical Society, 2007, 18, .	0.6	28
346	Improved and rapid synthesis of new coumarinyl chalcone derivatives and their antiviral activity. Tetrahedron Letters, 2007, 48, 8472-8474.	1.4	123
347	Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorganic and Medicinal Chemistry, 2007, 15, 1725-1731.	3.0	164
348	Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents. Bioorganic and Medicinal Chemistry, 2007, 15, 3134-3142.	3.0	119
349	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1956-1960.	2.2	70
350	Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (alkyloxy)methyl]-5-al transcriptase inhibitors. European Journal of Medicinal Chemistry, 2007, 42, 198-204.	5.5	16
351	Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways. Infection, Genetics and Evolution, 2007, 7, 600-603.	2.3	7
352	Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Research, 2007, 75, 179-187.	4.1	242
353	Inhibition of human immunodeficiency virus type 1 transcription by N-aminoimidazole derivatives. Virology, 2007, 365, 220-237.	2.4	8
354	Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 Td (Î±-cya Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 1778-1786.	6.4	44
355	Configurationally Restricted Bismacrocyclic CXCR4 Receptor Antagonists. Journal of Medicinal Chemistry, 2006, 49, 6162-6165.	6.4	97
356	A yeast-based model of Î±-synucleinopathy identifies compounds with therapeutic potential. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 312-318.	3.8	79
357	Replacement of the Metabolically Labile Methyl Esters in the Alkenyldiarylmethane Series of Non-Nucleoside Reverse Transcriptase Inhibitors with Isoxazolone, Isoxazole, Oxazolone, or Cyano Substituents. Journal of Medicinal Chemistry, 2006, 49, 5316-5323.	6.4	45
358	Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors, Part 7. Synthesis, Antiviral Activity, and 3D-QSAR Investigations of Novel 6-(1-Naphthoyl) HEPT Analogues. Chemical and Pharmaceutical Bulletin, 2006, 54, 1248-1253.	1.3	17
359	Synthesis and Anti-HIV Activity of Novel Cyclopentenyl Nucleoside Analogues of 8-Azapurine. Chemical and Pharmaceutical Bulletin, 2006, 54, 1418-1420.	1.3	9
360	Synthesis and Anti-HIV-1 and Anti-HCMV Activity of 1-Substituted 3-(3,5-Dimethylbenzyl)uracil Derivatives. Chemical and Pharmaceutical Bulletin, 2006, 54, 325-333.	1.3	25

#	Article	IF	Citations
361	HIV-1 Rev function as target for antiretroviral drug development. Current Opinion in HIV and AIDS, 2006, 1, 388-397.	3.8	3
362	Synthesis and primary antiviral activity evaluation of 3-hydrazono-5-nitro-2-indolinone derivatives. Arkivoc, 2006, 2006, 109-118.	0.5	21
363	Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings. Bioorganic and Medicinal Chemistry, 2006, 14, 2366-2374.	3.0	78
364	Synthesis and anti-HIV evaluation of the novel 2-(m-chlorobenzyl)-4-substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4, 5-e] [1, 2, 4]thiadiazines. Archives of Pharmacal Research, 2006, 29, 957-962.	6.3	21
365	Introduction to the Special Issue dedicated to Prof. Erik De Clercq for reaching the Professor Emeritus status at the Katholieke Universiteit Leuven. Antiviral Research, 2006, 71, 75-76.	4.1	1
366	Pyridine N-oxide derivatives inhibit viral transactivation by interfering with NF-Î¹B binding. Biochemical Pharmacology, 2006, 71, 1122-1135.	4.4	29
367	Nonnucleoside HIV-1 Reverse-Transcriptase Inhibitors. Part 5. Synthesis and anti-HIV-1 Activity of Novel 6-Naphthylthio HEPT Analogues.. ChemInform, 2006, 37, no.	0.0	0
368	Non-nucleoside HIV Reverse Transcriptase Inhibitors. Part 6. Synthesis and Anti-HIV Activity of Novel 2-[(Arylcarbonylmethyl)thio]-6-arylthio DABO Analogues.. ChemInform, 2006, 37, no.	0.0	1
369	Nitroimidazoles, Part 2. Chemistry and Biodiversity, 2006, 3, 515-526.	2.1	15
370	Ceramide Involvement in Apoptosis and Apoptotic Diseases. Mini-Reviews in Medicinal Chemistry, 2006, 6, 699-709.	2.4	57
371	Nonnucleoside HIV-1 Reverse-Transcriptase Inhibitors, Part 5. Synthesis and Anti-HIV-1 Activity of Novel 6-Naphthylthio HEPT Analogues. Chemical and Pharmaceutical Bulletin, 2005, 53, 886-892.	1.3	21
372	Non-nucleoside HIV Reverse Transcriptase Inhibitors, Part 6[1]: Synthesis and Anti-HIV Activity of Novel 2-[(Arylcarbonylmethyl)thio]-6-arylthio DABO Analogues. Archiv Der Pharmazie, 2005, 338, 457-461.	4.1	9
373	Identification of Novel Non-nucleoside Reverse Transcriptase Inhibitors Using Fragment-based Lead Generation. Medicinal Chemistry Research, 2005, 14, 475-487.	2.4	6
374	Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors, Part 4[1]. Synthesis and Anti-HIV Activity of N-1-Î²-Carbonyl-6-naphthyl-methyl Analogues of HEPT. Monatshefte FÃ¼r Chemie, 2005, 136, 1233-1245.	1.8	6
375	Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A. Journal of Virology, 2005, 79, 7777-7784.	3.4	89
376	A Novel and Efficient Approach to Discriminate between Pre- and Post-Transcription HIV Inhibitors. Molecular Pharmacology, 2005, 67, 1574-1580.	2.3	18
377	Aromatic Polycationic Molecules with Restricted Conformations: An Alternative Approach to Antiherpes Agents. Letters in Drug Design and Discovery, 2005, 2, 424-427.	0.7	0
378	Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action. Journal of Antimicrobial Chemotherapy, 2005, 55, 135-138.	3.0	95

#	Article	IF	Citations
379	Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. Journal of Antimicrobial Chemotherapy, 2005, 56, 847-855.	3.0	50
380	ANTIVIRAL POTENTIAL OF A NEW GENERATION OF ACYCLIC NUCLEOSIDE PHOSPHONATES, THE 6-[2-(PHOSPHONOMETHOXY)ALKOXY]-2,4-DIAMINOPYRIMIDINES. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 331-341.	1.1	66
381	Synthesis, Anti-HIV Activity, and Metabolic Stability of New Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 6140-6155.	6.4	33
382	Biologically active bisbenzylisoquinoline alkaloids from the root bark of Epinetrum villosum. Journal of Ethnopharmacology, 2005, 102, 89-94.	4.1	47
383	First Synthesis and Evaluation of the Inhibitory Effects of Aza Analogues of TSAO on HIV-1 Replication. Journal of Medicinal Chemistry, 2005, 48, 4276-4284.	6.4	38
384	Deoxythreosyl Phosphonate Nucleosides as Selective Anti-HIV Agents. Journal of the American Chemical Society, 2005, 127, 5056-5065.	13.7	114
385	Computational Strategies in Discovering Novel Non-nucleoside Inhibitors of HIV-1 RT. Journal of Medicinal Chemistry, 2005, 48, 3433-3437.	6.4	58
386	Design, Synthesis, Anti-HIV Activities, and Metabolic Stabilities of Alkenyldiarylmethane (ADAM) Non-nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 3149-3162.	6.4	33
387	How a Modification (8â€Azaâ€3â€deazaâ€2â€²â€deoxyguanosine) Influences the Quadruplex Structure of Hotoda's 6â€Mer TGGGAG with 5â€²â€•and 3â€²â€End Modifications. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 77-88.	1.1	7
388	Isothiazole Derivatives as Novel HIV Replication Inhibitors. Antiviral Chemistry and Chemotherapy, 2004, 15, 201-205.	0.6	11
389	Synthesis and antiviral activity of 1-substituted 3-(3,5-dimethylbenzyl)uracil against HIV-1. Nucleic Acids Symposium Series, 2004, 48, 3-4.	0.3	1
390	Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. Aids, 2004, 18, 2019-2028.	2.2	71
391	2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Research, 2004, 63, 79-84.	4.1	86
392	Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Il Farmaco, 2004, 59, 33-39.	0.9	69
393	Synthesis of New 2,3-Diaryl-1,3-thiazolidin-4-ones and anti-HIV Agents.. ChemInform, 2004, 35, no.	0.0	0
394	5-Alkyl-2-[(aryl and alkyloxycarbonylmethyl)thio]-6-(1-naphthylmethyl) Pyrimidin-4(3H)-ones as an Unique HIV Reverse Transcriptase Inhibitors of S-DABO Series.. ChemInform, 2004, 35, no.	0.0	0
395	Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones. Bioorganic Chemistry, 2004, 32, 536-548.	4.1	18
396	Synthesis and in vitro evaluation of S-acyl-3-thiopropyl prodrugs of Foscarnet. Bioorganic and Medicinal Chemistry, 2004, 12, 1393-1402.	3.0	9

#	Article	IF	Citations
397	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3173-3176.	2.2	46
398	Chemoenzymatic Syntheses of Homoâ€•and Heterodimers of AZT and d4T, and Evaluation of Their Antiâ€HIV Activity. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 701-714.	1.1	9
399	Potent Nonclassical Nucleoside Antiviral Drugs Based on theN,N-Diarylformamidine Concept. Journal of Medicinal Chemistry, 2004, 47, 1183-1192.	6.4	21
400	Phosphonates with Antiviral Activity. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1321-1327.	1.1	28
401	Structure Modifications of 6-Aminoquinolones with Potent Anti-HIV Activity1. Journal of Medicinal Chemistry, 2004, 47, 5567-5578.	6.4	45
402	Novel Inhibitors of HIV-1 Integration. Current Drug Metabolism, 2004, 5, 291-304.	1.2	51
403	Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis. Antiviral Therapy, 2004, 9, 57-65.	1.0	228
404	N-Aminoimidazole Derivatives Inhibiting Retroviral Replication via a Yet Unidentified Mode of Action. Journal of Medicinal Chemistry, 2003, 46, 1546-1553.	6.4	40
405	9-(2-Aryloxyethyl) Derivatives of Adenine - a New Class of Non-nucleosidic Antiviral Agents. Chemistry of Heterocyclic Compounds, 2003, 39, 1218-1226.	1.2	11
406	Antiretroviral Activity of Semisynthetic Derivatives of Glycopeptide Antibiotics. Journal of Medicinal Chemistry, 2003, 46, 2755-2764.	6.4	54
407	Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Il Farmaco, 2003, 58, 115-120.	0.9	62
408	Synthesis and anti-HIV Activity of 2,3-Diaryl-1,3-thiazolidin-4-(thi)one Derivatives.. ChemInform, 2003, 34, no.	0.0	0
409	Synthesis and anti-HIV Activity of 1-(2,6-Difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole Structurally-Related 1,2-Substituted Benzimidazoles.. ChemInform, 2003, 34, no.	0.0	0
410	Synthesis and anti-HIV Activity of 2,3-Diaryl-1,3-thiazolidin-4-ones.. ChemInform, 2003, 34, no.	0.0	0
411	Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors. Part 1. Synthesis and Structureâ€"Activity Relationship of 1-Alkoxymethyl-5-alkyl-6-naphthylmethyl Uracils as HEPT Analogues.. ChemInform, 2003, 34, no.	0.0	0
412	Heterocyclic rimantadine analogues with antiviral activity. Bioorganic and Medicinal Chemistry, 2003, 11, 5485-5492.	3.0	50
413	Are 5â€²-O-Carbamate-2â€²,3â€²-dideoxythiacytidine New Anti-HIV and Anti-HBV nucleoside Drugs or Prodrugs?. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2459-2463.	2.2	12
414	Synthesis of New Homo and Heterodimers of 2â€²,3â€²-Dideoxyinosine (ddi) Using Ester Linkages. Nucleosides, Nucleotides and Nucleic Acids, 2003, 22, 829-831.	1.1	4

#	Article	IF	Citations
415	Inhibition of Human Immunodeficiency Virus by a New Class of Pyridine Oxide Derivatives. Antimicrobial Agents and Chemotherapy, 2003, 47, 2951-2957.	3.2	30
416	Synthesis and Antiviral Activity of 1,3-Disubstituted Uracils against HIV-1 and HCMV. Antiviral Chemistry and Chemotherapy, 2003, 14, 271-279.	0.6	21
417	Novel Human Immunodeficiency Virus (HIV) Inhibitors That Have a Dual Mode of Anti-HIV Action. Antimicrobial Agents and Chemotherapy, 2003, 47, 3109-3116.	3.2	26
418	Synthesis and Antiviral Activities of 3-Aralkyl-Thiomethylimidazo[1,2-b]Pyridazine Derivatives. Antiviral Chemistry and Chemotherapy, 2003, 14, 177-182.	0.6	5
419	Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations. Journal of Virology, 2003, 77, 11459-11470.	3.4	94
420	Potent and Selective Inhibition of HIV and SIV by Prostratin Interacting with Viral Entry. Antiviral Chemistry and Chemotherapy, 2003, 14, 321-328.	0.6	16
421	Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors: Part I. Synthesis and Structure-Activity Relationship of 1-Alkoxymethyl-5-alkyl-6-naphthylmethyl Uracils as HEPT Analogues. Chemical and Pharmaceutical Bulletin, 2003, 51, 779-789.	1.3	42
422	Discovery of a Tat HIV-1 Inhibitor through Computer-Aided Drug Design. Spectroscopy, 2003, 17, 639-645.	0.8	8
423	Inhibition of Human Immunodeficiency Virus Type 1 Integration by Diketo Derivatives. Antimicrobial Agents and Chemotherapy, 2002, 46, 3292-3297.	3.2	52
424	env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors. Antimicrobial Agents and Chemotherapy, 2002, 46, 3954-3962.	3.2	39
425	Antiretrovirus Activity of a Novel Class of Acyclic Pyrimidine Nucleoside Phosphonates. Antimicrobial Agents and Chemotherapy, 2002, 46, 2185-2193.	3.2	63
426	Synthesis of New Covalently Bound Îº-Carrageenanâˆ'AZT Conjugates with Improved Anti-HIV Activities. Journal of Medicinal Chemistry, 2002, 45, 1275-1283.	6.4	69
427	Design, Synthesis, Structureâˆ'Activity Relationships, and Molecular Modeling Studies of 2,3-Diaryl-1,3-thiazolidin-4-ones as Potent Anti-HIV Agents. Journal of Medicinal Chemistry, 2002, 45, 5410-5413.	6.4	151
428	Chemical studies of essential oils of Juniperus oxycedrus ssp. badia. Journal of Ethnopharmacology, 2002, 81, 129-134.	4.1	53
429	Synthesis and biological activity of some 4-substituted 1-[1-(2,3-dihydroxy-1-propoxy)methyl-1,2,3-triazol-(4 & 5)-ylmethyl]-1H-pyrazolo[3,4-d]pyrimidines. Il Farmaco, 2002, 57, 27-32.	0.9	36
430	Synthesis and antiviral activity evaluation of some new 6-substituted 3-(1-adamantyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles. Il Farmaco, 2002, 57, 253-257.	0.9	166
431	Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Il Farmaco, 2002, 57, 747-751.	0.9	75
432	Synthesis and anti-HIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Il Farmaco, 2002, 57, 819-823.	0.9	86

#	Article	IF	Citations
433	New Class of HIV Integrase Inhibitors that Block Viral Replication in Cell Culture. Current Biology, 2002, 12, 1169-1177.	3.9	100
434	Anti-HIV Activity of Thiosemicarbazone and Semicarbazone Derivatives of (Â±)-3-Menthone. Archiv Der Pharmazie, 2002, 335, 183.	4.1	63
435	1,2,4-Triazole Derivatives Inhibiting the Human Immunodeficiency Virus Type 1 (HIV-1) in vitro. Helvetica Chimica Acta, 2002, 85, 1883.	1.6	20
436	Title is missing!. Helvetica Chimica Acta, 2002, 85, 2961-2974.	1.6	28
437	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazonesâ€“thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 723-727.	2.2	55
438	Halogenated sesquiterpenes from the red alga Laurencia obtusa. Tetrahedron, 2002, 58, 6749-6755.	1.9	37
439	SYNTHESIS AND BIOLOGICAL ACTIVITY OF 4-SUBSTITUTED 1-[1-(2-HYDROXYETHOXY)- METHYL-1,2,3-TRIAZOL-(4) Tj ETQq1 1 0.7843 1797-1810.	1.1	18
440	New 3â€˜-Azido-3â€˜-deoxythymidin-5â€˜-ylO-(Ï‰-Hydroxyalkyl) Carbonate Prodrugs:Â Synthesis and Anti-HIV Evaluation. Journal of Medicinal Chemistry, 2001, 44, 777-786.	6.4	35
441	SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME 4-SUBSTITUTED 1-[1-(4-HYDROXYBUTYL)-1,2,3-TRIAZOL-(4) Tj ETQq1 1 0.7843 1811-1821.	1.1	16
442	Correlation of Anti-HIV Activity with Anion Spacing in a Series of Cosalane Analogues with Extended Polycarboxylate Pharmacophores. Journal of Medicinal Chemistry, 2001, 44, 703-714.	6.4	26
443	SYNTHESIS AND ANTI-HIV ACTIVITY OF NEW MODIFIED 1,2,3-TRIAZOLE ACYCLONUCLEOSIDES. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 1949-1960.	1.1	95
444	New 3â€˜-Azido-3â€˜-deoxythymidin-5â€˜-yl O-(4-Hydroxyalkyl or -Alkenyl or -Alkylepoxide) Carbonate Prodrugs:â€‰ Synthesis and Anti-HIV Evaluation. Journal of Medicinal Chemistry, 2001, 44, 3014-3021.	6.4	27
445	Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype. Aids, 2001, 15, 553-561.	2.2	16
446	3-Benzamido, Ureido and Thioureidoimidazo[1,2-a]pyridine Derivatives as Potential Antiviral Agents.. Chemical and Pharmaceutical Bulletin, 2001, 49, 1631-1635.	1.3	12
447	Synthesis and anti-HIV activity of a bile acid analog of cosalane. Tetrahedron, 2001, 57, 9385-9391.	1.9	24
448	Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1793-1796.	2.2	214
449	Synthesis and anti-HIV activity of cosalane analogues incorporating two dichlorodisalicylmethane pharmacophore fragments. Bioorganic and Medicinal Chemistry, 2001, 9, 2827-2841.	3.0	8
450	Pyridazines 92. Synthesis of dialkyldipyridazinodiazepinones as potential HIVâ€1 reverse transcriptase inhibitors. Journal of Heterocyclic Chemistry, 2001, 38, 125-130.	2.6	4

#	Article	IF	Citations
451	Antiviral activity against human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) of ethnobotanically selected Ethiopian medicinal plants. Phytotherapy Research, 2001, 15, 62-69.	5.8	129
452	Synthesis of 3-Nitrosoimidazo[1,2-a]pyridine Derivatives as Potential Antiretroviral Agents. Archiv Der Pharmazie, 2001, 334, 224-228.	4.1	17
453	Synthesis and anti-HIV activity of 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene) amino]-N(4,6-dimethyl-2-pyrimidinyl)-benzene sulfonamide and its derivatives. European Journal of Pharmaceutical Sciences, 2001, 14, 313-316.	4.0	53
454	Anti-HIV-1 Activity of Benzothiadiazine Dioxide. Antiviral Chemistry and Chemotherapy, 2001, 12, 347-351.	0.6	6
455	Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. Aids, 2001, 15, 33-45.	2.2	38
456	Synthesis, Biological Activity, Pharmacokinetic Properties and Molecular Modelling Studies of Novel 1H,3H-Oxazolo[3,4-a]Benzimidazoles: Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Antiviral Chemistry and Chemotherapy, 2001, 12, 169-174.	0.6	9
457	Synthesis, Antiretroviral and Antioxidant Evaluation of a Series of New Benzo[b]furan Derivatives. Arzneimittelforschung, 2001, 51, 156-162.	0.4	3
458	Evaluating Clinical Isolates for Their Phenotypic and Genotypic Resistance Against Anti-HIV Drugs. , 2000, 24, 223-258.		27
459	Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2149-2152.	2.2	5
460	Anti-HIV activity of a series of cosalane amino acid conjugates. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2505-2508.	2.2	7
461	Synthesis and anti-HIV activity of cosalane analogues incorporating nitrogen in the linker chain. Bioorganic and Medicinal Chemistry, 2000, 8, 191-200.	3.0	15
462	In vitro evaluation of the effect of temporary removal of HIV drug pressure. Antiviral Research, 2000, 46, 215-221.	4.1	11
463	4 Viral entry as the primary target of anti-HIV activity of chicoric acid and its tetra-acetyl esters. Antiviral Research, 2000, 46, A36.	4.1	1
464	Viral Entry as the Primary Target for the Anti-HIV Activity of Chicoric Acid and Its Tetra-Acetyl Esters. Molecular Pharmacology, 2000, 58, 641-648.	2.3	109
465	Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. Antimicrobial Agents and Chemotherapy, 2000, 44, 2109-2117.	3.2	101
466	1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. Comptes Rendus De L'AcadÃ©mie Des Sciences SÃ©rie 3, Sciences De La Vie, 2000, 323, 883-894.	0.8	63
467	Polyanionic (i.e., Polysulfonate) Dendrimers Can Inhibit the Replication of Human Immunodeficiency Virus by Interfering with Both Virus Adsorption and Later Steps (Reverse Transcriptase/Integrase) in the Virus Replicative Cycle. Molecular Pharmacology, 2000, 58, 1100-1108.	2.3	149
468	Potent Anti-HIV (Type 1 and Type 2) Activity of Polyoxometalates:Â Structureâ^'Activity Relationship and Mechanism of Action. Journal of Medicinal Chemistry, 2000, 43, 778-783.	6.4	65

#	Article	IF	Citations
469	A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Molecular Pharmacology, 2000, 57, 116-24.	2.3	57
470	Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Molecular Pharmacology, 2000, 58, 1100-8.	2.3	44
471	Antiviral Research. Satellite symposium: Clinical update on antiviral drugs. IDrugs: the Investigational Drugs Journal, 2000, 3, 760-1.	0.7	0
472	Synthesis and Biological Activity of Novel 1H,3H-Thiazolo[3,4-a]Benzimidazoles: Non-nucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors. Antiviral Chemistry and Chemotherapy, 1999, 10, 211-217.	0.6	50
473	Synthesis and anti-HIV activity of 1,1,3-trioxo-2 H ,4 H -thieno[3,4- e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 1999, 7, 2811-2822.	3.0	62
474	Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. International Journal of Pharmaceutics, 1999, 186, 127-136.	5.2	27
475	Inhibition of Human Immunodeficiency Virus Type (HIV-1) Replication by some Diversely Functionalized Spirocyclopropyl Derivatives. Archiv Der Pharmazie, 1999, 332, 163-166.	4.1	21
476	Synthesis and Screening for Anti-HIV Activity of Some N-Mannich Bases of Isatin Derivatives. Chemotherapy, 1999, 45, 192-196.	1.6	71
477	Synthesis and Anti-HIV Activity of Cosalane Analogues with Substituted Benzoic Acid Rings Attached to the Pharmacophore through Methylene and Amide Linkers. Journal of Organic Chemistry, 1999, 64, 5858-5866.	3.2	14
478	Chicoric Acid Analogues as HIV-1 Integrase Inhibitors. Journal of Medicinal Chemistry, 1999, 42, 1401-1414.	6.4	149
479	Extension of the Polyanionic Cosalane Pharmacophore as a Strategy for Increasing Anti-HIV Potency. Journal of Medicinal Chemistry, 1999, 42, 1767-1777.	6.4	15
480	Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. Aids, 1999, 13, 1477-1483.	2.2	77
481	Synthesis of aryl semicarbazone of 4-aminoacetophenone and their anti-HIV activity. Pharmaceutica Acta Helvetiae, 1998, 73, 215-218.	1.2	15
482	Synthesis of (Z) and (E) Î±-alkenyl phosphonic acid derivatives of purines and pyrimidines. Tetrahedron, 1998, 54, 3807-3816.	1.9	72
483	Polyanion Inhibitors of HIV and Other Viruses. 7. Polyanionic Compounds and Polyzwitterionic Compounds Derived from Cyclodextrins as Inhibitors of HIV Transmission. Journal of Medicinal Chemistry, 1998, 41, 4927-4932.	6.4	48
484	Novel 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine Derivatives as Non-Nucleoside Reverse Transcriptase Inhibitors That Inhibit Human Immunodeficiency Virus Type 1 Replication. Journal of Medicinal Chemistry, 1998, 41, 4109-4117.	6.4	39
485	Broad-Spectrum Antiviral Activity and Mechanism of Antiviral Action of the Fluoroquinolone Derivative K-12. Antiviral Chemistry and Chemotherapy, 1998, 9, 403-411.	0.6	49
486	Synthesis, Structure and in Vitro Anti-Human Immunodeficiency virus Activity of Novel 3-Methyl-1H,3H-Thiazolo[3,4-a]Benzimidazoles. Antiviral Chemistry and Chemotherapy, 1998, 9, 431-438.	0.6	27

#	Article	IF	Citations
487	Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir). Molecular Pharmacology, 1998, 53, 340-345.	2.3	118
488	1,1,3-Trioxo-2 H ,4 H -Thieno[3,4- e][1,2,4]Thiadiazine (TTD) Derivatives: a New Class of Nonnucleoside Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitors with Anti-HIV-1 Activity. Antimicrobial Agents and Chemotherapy, 1998, 42, 618-623.	3.2	48
489	Conversion of 2â€²,3â€²-dideoxyadenosine (ddA) and 2â€²,3â€²-didehydro-2â€²,3â€²-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Letters, 1997, 410, 324-328.	2.8	55
490	SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. Antimicrobial Agents and Chemotherapy, 1997, 41, 262-268.	3.2	47
491	Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice. Antimicrobial Agents and Chemotherapy, 1997, 41, 611-616.	3.2	29
492	S-Adenosylhomocysteine Hydrolase Inhibitors Interfere with the Replication of Human Immunodeficiency Virus Type 1 through Inhibition of the LTR Transactivation. Molecular Pharmacology, 1997, 52, 1157-1163.	2.3	27
493	Studies into the synthesis of derivatives of 4-amino-2,3-dihydroisothiazole 1,1-dioxides and 4-amino-1,2-oxathiole 2,2-dioxides: The search for linked Ï€-system containing analogues as potential inhibitors of HIV-1 reverse transcriptase. Tetrahedron, 1997, 53, 17795-17814.	1.9	37
494	Disulfide-containing macrolides that inhibit a late stage of the replicative cycle of human immunodeficiency virus. Antiviral Research, 1997, 34, A48.	4.1	0
495	New 1,1,3-trioxo-2H,4H-thieno[3,4-e]thiadiazine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Research, 1997, 34, A56.	4.1	0
496	Human immunodeficiency virus gp120 as the primary target of action of AR177 (Zintevir). Antiviral Research, 1997, 34, A57.	4.1	1
497	Synthesis and anti-HIV activity of some new aminoadamantane heterocycles. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1887-1890.	2.2	15
498	Î±â€Amino acids derived from ornithine as building blocks for peptide synthesis. Chemical Biology and Drug Design, 1997, 49, 183-189.	1.1	0
499	SYNTHESIS OFN⁶-ALKYLATED ADENOSINE DERIVATIVES. Nucleosides & Nucleotides, 1996, 15, 1863-1869.	0.5	6
500	Amino acids derived from ornithine. International Journal of Peptide Research and Therapeutics, 1995, 2, 206-208.	0.1	2
501	Synthesis and antiviral evaluation of 3â€²-substituted thymidine analogues derived from 3â€²-amino-3â€²-deoxythymidine. Tetrahedron, 1995, 51, 5369-5380.	1.9	4
502	Synthesis and Antiviral Evaluation of 3'-Substituted Thymidine Analogues Derived from 3'-Amino-3'-deoxythymidine. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 541-544.	1.1	2
503	The N1-(3'-Deoxythymidin-3'-yl)-N2-cyano-N3-(5'-deoxythymidin-5'-yl) Guanidine Dimeric Building Block in Automated DNA Synthesis and Mass Spectrometric Analysis of Its Integrity. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 1037-1040.	1.1	0
504	2â€²-Deoxyuridines with a 5-Heteroaromatic Substituent: Synthesis and Biological Evaluation. Antiviral Chemistry and Chemotherapy, 1995, 6, 262-270.	0.6	8

#	Article	IF	Citations
505	Synthesis and Antiviral Activities of Some New 5-Heteroaromatic Substituted Derivatives of 2'-Deoxyuridine. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 525-528.	1.1	10
506	Synthesis, enzymatic stability and physicochemical properties of oligonucleotides containing a N-cyanoguanidine linkage.. Tetrahedron, 1994, 50, 7231-7246.	1.9	10
507	Mixed oligonucleotide analogues with an acyclic carbohydrate moiety and a N-cyanoguanidine functionality. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1203-1206.	2.2	2
508	Dimeric building blocks with N-cyanoguanidine linkage for oligonucleotide synthesis. Tetrahedron Letters, 1992, 33, 7609-7612.	1.4	16
509	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication. Journal of Medicinal Chemistry, 1991, 34, 2383-2389.	6.4	102